The year in charts

Private & Public Swiss Biotech Companies

Total Swiss Biotech Companies

Public Swiss Biotech Companies

Private Swiss Biotech Companies

You may also be interested in

Total revenues remain strong at CHF 7.2 billion (CHF 7.3 billion in 2023) Record CHF 833 million raised by privately funded companies drives 22% overall rise in capital investment to CHF 2.5 billion (CHF 2.0 billion in 2023) Alentis Therapeutics (CHF 163 million) and SixPeaks Bio (CHF 102 million) lead the way in the private financing rounds Despite market headwinds, some public companies report n
May 5, 2025

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We recently noticed fraudulent emails to steal your passwords of your Microsoft, Outlook or similar accounts via phishing emails. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals will ask y
October 8, 2024

Christian Moser Nikles, Patent Expert & Christel Aebischer, Patent Expert | Swiss Federal Institute of Intellectual Property
SIX Swiss Exchange reviews publicly listed companies included in ‘Highlights of 2024: Year in Review’ (Pages 52 to 55). While Santhera and Kuros made good progress, SIX recognizes the notable success of Basilea which, 20 years after its IPO in 2004, has reported increasingly robust profits.
May 5, 2025

Sirpa Tsimal, Director Investment Promotion | Switzerland Global Enterprise
Switzerland Global Enterprise’s Sirpa Tsimal talks to Leila Schwery and Michael Hübner of Johnson & Johnson about the company’s commitment to fostering global partnerships, the evolution of its manufacturing and supply chain strategies, and the critical role Switzerland plays in shaping its global capabilities.
May 5, 2025

Jan Lucht, Head Biotechnology | scienceindustries
Biotechnology applications are expanding globally into many areas beyond the pharmaceutical sector. A growing range of products meet consumer demands while contributing to sustainability and climate protection. However, the current European authorization process for these innovative products is unnecessarily burdensome and limits market access. Leading European business organizations have come tog
May 5, 2025

Michael Altorfer, CEO & Marta Gehring, Special projects | Swiss Biotech Association
In the dynamic landscape of biotechnology, Switzerland stands out not only for the power of its innovation but also for its collaborative spirit. Despite the country accounting for just 0.5% of the world’s GDP and 0.1% of its population, Switzerland’s life sciences ecosystem punches well above its weight. Swiss biotech thrives by forging alliances that harmonize efforts, amplify outcomes, and
May 5, 2025